Helmer, Markus http://orcid.org/0000-0001-9680-0595
Warrington, Shaun http://orcid.org/0000-0002-7198-8162
Mohammadi-Nejad, Ali-Reza
Ji, Jie Lisa
Howell, Amber
Rosand, Benjamin
Anticevic, Alan
Sotiropoulos, Stamatios N. http://orcid.org/0000-0003-4735-5776
Murray, John D. http://orcid.org/0000-0003-4115-8181
Article History
Received: 7 May 2023
Accepted: 28 January 2024
First Online: 21 February 2024
Competing interests
: The authors declare the following competing interests: M.H. and J.L.J. are currently employed by Manifest Technologies. A.A. and J.D.M. hold equity with Neumora Therapeutics (formerly BlackThorn Therapeutics) and are co-founders of Manifest Technologies. J.D.M. and A.A. are co-inventors on the patent Methods and tools for detecting, diagnosing, predicting, prognosticating, or treating a neurobehavioral phenotype in a subject, U.S. Application No.16/149,903, filed on October 2, 664 2018, U.S. Application for PCT International Application No.18/054, 009 filed on October 2, 2018. A.A., J.D.M. and J.L.J are co-inventors on the patent Systems and Methods for Neuro-Behavioral Relationships in Dimensional Geometric Embedding(N-BRIDGE), PCT International Application No.PCT/US2119/022110, filed March 13, 2019. A.A., J.D.M., M.H. and J.L.L. are co-inventors on the patent Methods of Identifying Subjects for Inclusion and/or Exclusion in a Clinical Trial, Application No.: 63/533,888, filed August 21, 2023. All other authors declare no competing interests.